Amikacin IV Dosing for CAUTI with Normal Creatinine
For catheter-associated urinary tract infections in patients with normal renal function, administer amikacin 15 mg/kg/day IV divided into either 7.5 mg/kg every 12 hours or 5 mg/kg every 8 hours, not exceeding 1.5 grams/day, infused over 30-60 minutes. 1
Dosing Algorithm
Standard Dosing Regimen
- Total daily dose: 15 mg/kg/day (maximum 1.5 g/day)
- Divided dosing options:
- 7.5 mg/kg IV every 12 hours, OR
- 5 mg/kg IV every 8 hours
- Infusion time: 30-60 minutes in adults 1
Specific Dosing for Uncomplicated UTI
For uncomplicated urinary tract infections specifically, a reduced dose of 250 mg IV twice daily may be used 1. However, CAUTI is classified as a complicated UTI due to the presence of a foreign body (catheter), so the standard 15 mg/kg/day dosing is more appropriate.
Treatment Context
The 2024 European Association of Urology guidelines recommend aminoglycosides as part of combination therapy for complicated UTIs with systemic symptoms, specifically:
- Amoxicillin plus an aminoglycoside, OR
- A second-generation cephalosporin plus an aminoglycoside, OR
- An IV third-generation cephalosporin 2
CAUTI is a complicated UTI with significant mortality risk (approximately 10%) 2, justifying aggressive empiric therapy with aminoglycosides in combination regimens.
Treatment Duration
- 7 days for patients with prompt symptom resolution 3
- 10-14 days for delayed response 3
- 14 days for men when prostatitis cannot be excluded 2
Critical Management Points
Catheter Management
If the catheter has been in place ≥2 weeks at CAUTI onset and is still indicated, replace it before initiating antimicrobials 3. This intervention:
- Hastens symptom resolution
- Reduces risk of subsequent CA-bacteriuria and CA-UTI
- Provides more accurate culture results from fresh catheter urine
Monitoring Requirements
- Peak concentrations (30-90 minutes post-infusion): Keep <35 mcg/mL
- Trough concentrations (just before next dose): Keep <10 mcg/mL
- Monitor renal function, auditory, and vestibular function if treatment extends beyond 10 days 1
Therapeutic Drug Monitoring
While the FDA label provides standard dosing, therapeutic drug monitoring should be performed when possible to optimize peak/MIC ratios 4. Early achievement of optimal peak/MIC ≥8 improves clinical and microbiological outcomes 4.
Common Pitfalls to Avoid
- Don't use the 250 mg twice daily dose for CAUTI: This lower dose is only for uncomplicated UTI; CAUTI requires full 15 mg/kg/day dosing due to its complicated nature
- Don't skip catheter replacement: If the catheter has been in place ≥2 weeks, replacing it before treatment significantly improves outcomes
- Don't obtain cultures from old catheters: Culture specimens should come from freshly placed catheters when feasible 3
- Don't exceed 15 mg/kg/day total: This is the maximum daily dose regardless of dosing frequency 1
Safety Considerations
Recent data suggests once-daily amikacin for UTI carries low AKI risk (5.6% incidence), even in patients with pre-existing renal impairment 5. The nephrotoxicity concerns historically associated with aminoglycosides may be overstated for UTI treatment when appropriate dosing and monitoring are employed.
Obtain urine culture before initiating therapy 2, 3 to allow for de-escalation based on susceptibility results, as the microbial spectrum in CAUTI is broad and resistance is common.